Qualification for adjuvant therapy in luminal HER2-negative early breast cancer (stages I and II in the 8th edition of the American Joint Cancer Committee (AJCC) TNM classification for breast cancer [31]) remains one of the major clinical issues. The gene discussed is ERBB2; the disease is breast cancer.